# A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

> **NCT01532869** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 87 (actual)

## Conditions studied

- Sclerosis, Systemic

## Interventions

- **DRUG:** Placebo
- **DRUG:** tocilizumab [RoActemra/Actemra]
- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT01532869
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2014-01
- **Final completion:** 2015-08
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01532869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01532869, "A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01532869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*